{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"125.6","value":"449"}]}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"128.7","value":"532"}]}],"title":"Cycle 2 (n = 21)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with available serum concentration data","reportingStatus":"POSTED","timeFrame":"Cycle 1, day 8, 6 to 8 hours after the dose step to 28 μg/day, and Cycle 2, day 1, 6 to 8 hours after blinatumomab infusion","title":"Steady State Concentration of Blinatumomab","type":"SECONDARY","unitOfMeasure":"pg/mL"}